期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

PPARα/γ双重激动剂与2型糖尿病 被引量：2

Peroxisome Proliferator Activated Receptor α/γ Dual Agonists and Type 2 Diabetes Mellitus
下载PDF
导出
摘要 越来越多的研究表明,肥胖和胰岛素抵抗能导致2型糖尿病的发病,对2型糖尿病的治疗方法也在不断改进。最近研究表明,过氧化物酶体增殖物激活受体α/γ(PPARα/γ)双重激动剂具有降血脂、改善胰岛素抵抗、抗炎、抗动脉粥样硬化等作用,是一类治疗糖尿病的新药,对其相关研究将有助于今后临床上更好的治疗2型糖尿病。 Accumulated researches demostrated that obesity and insulin resistance（IR） can result in the genesis of type 2 diabetes mellitus（T2DM）. Therefore,there has much progress on the treatment of T2DM. Recent studies show that PPARα/γ dual agonists have many effects such as decreasing blood fat, improving insulin resistance, anti-inflammatory, anti-artherosclerosis （AS） and so on, and it is a new kind of drug, having distinct effects on T2 DM. So, the researches related to PPARα/γ dual agonists will do good to the therapy for T2DM in clinic.
作者 杨俊 邹秀兰
机构地区 三峡大学医学院 宜昌市第一人民医院内分泌科
出处 《医学综述》 2008年第16期2492-2496,共5页 Medical Recapitulate
关键词 2型糖尿病 胰岛素抵抗 肥胖 过氧化物酶体增殖物激活受体α/γ双重激动剂 Type 2 diabetes mellitus Insulin resistance Obesity Peroxisome proliferator activated receptor α/γ dual agonists
分类号 R587.1 [医药卫生—内分泌]
  • 相关文献

参考文献27

  • 1Desvergne B, Michalik L, Wahli W. Be fit or be sick: peroxisome proliferator-activated receptors are down the road [ J ]. Mol Endocrinol,2004,18(6) :1321-1332.
  • 2Argmann CA, Cock TA, Auwerx J. Peroxisome proliferator-activated receptor gamma: the more the merrier? [ J]. Eur J Clin Invest, 2005,35 (2) :82-92.
  • 3Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase e-xpression and plasma concentrations of adiponectin, an adipose-derived protein[J]. Diabetes,2001,50 (9) :2094-2099.
  • 4Teranishi T, Ohara T, Maeda K, et al. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes meUitus [ J ]. Metabolism,2007, 56(10) :1418-1424.
  • 5Madea N, Takabashi M, Funabashj T, et al. PPAR3, ligands increase expression and plasma concentrations of adiponectin, an adipose derived protein [ J ]. Diabetes,2001,50 (9) :2094-2099.
  • 6Schuster H, Faqerberq B, Edwards S, et al. Tesaglitazar, a dual peroxisome pr-oliferator-activated receptor α/γ agonist,improves apolipopretein levels in n-on-diabetic subjects with insulin resistance [ J ]. Atherescleresis,2008,197 ( 1 ) :355-362.
  • 7Murakami K,Tobe K,Ide T,et al. A novel insulin sensitiser acts as a coligand for peroxisome proliferator actvated receptorα (PPARα) and PPARγ[ J]. Diabetes,1998,47(12) :1841-1847.
  • 8Shinkai H ,Onogi S, Tanaka M, et al. Isoxazolidine-3,5-dione and noncyclic 1,3-dicarbonyl compounds as hypoglycemic agents [ J ]. J Med Chem, 1998,41 ( 11 ) : 1927-1933.
  • 9Devasthale PV, Chen S, Jeon Y, et al. Design and synthesis of N- [ (4-meth-oxyphenoxy) carbonyl ] -N-[ [ 4-[ 2-( 5-methyl-2-phenyl-4-oxazolyl ) ethoxy ] phenyl ] methyl ] glycine [ Muraglitazar/ BMS-298585 ], a novel perexisome proliferator activated receptor a and 7 dual agonist with efficacious glucose and lipid lowering activities[J]. J Med Chem,2005,48 (6):2248-2250.
  • 10Liu K, Xu L, Berger JP, et al. Discovery of a novel series of peroxisome prolfferator activated receptorα/γ dual agonists for the treatment of type 2 diabetes and dyslipidemia[ J]. J Med Chem,2005, 48 (7) :2262-2265.

二级参考文献32

  • 1[12]Ciaraldi TP, Gilmore A, Olefsky JM et al. In vitro studies on the action s of CS-045. A new antidiabetic agent. Metabolism, 1990;39(10):1056～62
  • 2[13]Burant2 CF, Screenan S, Hirano K et al. Troglitazone action is independent of adipose tissue. J Clin Invest, 1997;100(11):2900～8
  • 3[14]Lee MK, Olefsky JM. Acute effects of troglitazone on in vivo insulin action in normal rats. Metabolism, 1995;44(9):1166～9
  • 4[15]Preininger K, Stingl P, Englisch R et al. Acute troglitazone action in isolated perfused rat liver. Br J Pharmacol, 1999;126(1):372～8
  • 5[16]Henry RR. Thiazolidinedione. Endocrinol Metab Clin North Am, 1997;26(3):9553～73
  • 6[17]Gimble JM, Robinson CE, Wu X et al. Peroxisome proliferatior-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol, 1996;50(5):1087～94
  • 7[18]Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther, 2000;22(10):1151～68
  • 8[19]Forman, BM, Tontonoz P, Chen J et al. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell, 1995;83(5): 813～9
  • 9[20]Houseknecht KL, Vanden, Heuvel JP et al. Dietary conjugated linoleic acid normalizes impaired glucose tolerance in the Zucker diabetic fatty fa/fa rat. Biochem Biophys Res Commun, 1998;244(3):678～82
  • 10[21]Ryder JW, Portocarrero CP, Song XM et al. I somer-specific antidiabetic properties of conjugated linoleic acid. Improved glucose tolerance,skeletal muscle insulin action, and UCP-2 gene expression. Diabetes, 2001;50(5):1149～57

共引文献19

同被引文献38

  • 1Glass CK,Ogawa S.Combinatorial roles of nuclear receptors in inflammation and immunity.Nat Rev Immunol,2006,6:44-55.
  • 2Dressel U,Allen TL,Pippal JB,et al.The peroxisome proliferatoractivated receptor beta/delta agunist,GW501516,regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.Mol Endocrinol,2003,17:2477-2493.
  • 3Cho N,Momose Y.Peroxisome proliferator-activated receptor gamma agonists as insulin sensitizers:From the discovery to recent progress.Curr Top Med Chem,2008,8:1483-1507.
  • 4Zieleniak A,Wojcik M,Wozniak LA.Structure and physiological functions of the human perexisome proliferator-activated receptor gamma.Arch Immunol Ther Exp (Warsz),2008,56:331-345.
  • 5Reifel-Miller A,Otto K,Hawkins E,et al.A pemxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.Mol Endocrinol,2005,19:1593-1605.
  • 6Pickup JC.Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes.Diabetes Care,2004,27:813-823.
  • 7Valverde AM,Benito M,Lorenzo M.The brown adipose cell:A model for umterstanding the molecular mechanisms of insulin resistance.Acta Physiol Scand,2005,183:59-73.
  • 8Gross B,Staels B.PPAR agonists:Multimodal drugs for the treatment of type-2 diabetes.Best Pract Res Clin Endocrinol Metab,2007,21:687-710.
  • 9Weyer C,Foley JE,Bogardus C,et al.Enlarged subcutaneous abdominal adipocyte size,but not obesity itself,predicts type Ⅱ diabetes independent of insulin resistance.Diabetologia,2000,43:1498-1506.
  • 10Ahshuler D,Hirschhorn.IN,Klannemark M,et al.The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes.Nat Genet,2000,26:76-80.

引证文献2

二级引证文献9

医学综述
2008年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部